4-({4-[(1-benzyl-4,5-dimethyl-1H-imidazol-2-yl)thio]-3-chlorophenyl}amino)-7-{[3-(dimethylamino)propyl]amino}-6-methoxyquinoline-3-carbonitrile | 1125454-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-({4-[(1-benzyl-4,5-dimethyl-1H-imidazol-2-yl)thio]-3-chlorophenyl}amino)-7-{[3-(dimethylamino)propyl]amino}-6-methoxyquinoline-3-carbonitrile
• 英文别名: 4-({4-[(1-benzyl-4,5-dimethyl-1H-imidazol-2-yl)sulfanyl]-3-chlorophenyl}amino)-7-{[3-(dimethylamino)propyl]amino}-6-methoxyquinoline-3-carbonitrile；4-[4-(1-benzyl-4,5-dimethylimidazol-2-yl)sulfanyl-3-chloroanilino]-7-[3-(dimethylamino)propylamino]-6-methoxyquinoline-3-carbonitrile
• CAS: 1125454-93-4
• 化学式: C₃₄H₃₆ClN₇OS
• 分子量: 626.225
• InChiKey: DQQSOBJJPXQOCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.9
• 重原子数：
  44
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  116
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• 3-Cyanoquinolines, Methods for Preparation and Use as Insulin-like Growth Factor Inhibitors
  申请人：Mayer Scott Christian

  公开号：US20090264427A1

  公开（公告）日：2009-10-22

  Imidazole-substituted 4-anilino-3-cyanoquinolines are described, which selectively inhibit IFGR kinase activity and are useful for treating disorders associated with IGFR kinases.

  描述了咪唑取代的4-苯胺基-3-氰基喹啉类化合物，其选择性抑制IGFR激酶活性，并可用于治疗与IGFR激酶相关的疾病。
• Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer
  申请人：Grunt Thomas

  公开号：US20090325877A1

  公开（公告）日：2009-12-31

  A pharmaceutical combination product is disclosed that comprises a receptor tyrosine kinase inhibitor and a fatty acid synthase inhibitor, and to the use thereof in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.
• [EN] COMBINATION PRODUCT OF RECEPTOR TYROSINE KINASE INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR FOR TREATING CANCER<br/>[FR] PRODUIT DE COMBINAISON D'UN INHIBITEUR DE TYROSINE KINASE DE RÉCEPTEUR ET D'UN INHIBITEUR D'ACIDE GRAS SYNTHASE POUR LE TRAITEMENT DU CANCER
  申请人：WYETH CORP

  公开号：WO2009151910A2

  公开（公告）日：2009-12-17

  A pharmaceutical combination product is disclosed that comprises a receptor tyrosine kinase inhibitor and a fatty acid synthase inhibitor, and to the use thereof in the manufacture of a medicament for use in the treatment or prophylaxis of cancer.